Who
Nancy Thornberry
Director
Company insider
Files Form 4 as: Director, Denali Therapeutics; Director, Schrodinger; Director, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 10 Feb 2020
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $247K10,824 at $22.85 | filing |
| 2 Sep 2026filed 4 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K615 at $23.74 | filing |
| 2 Sep 2026filed 4 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $247K10,824 at $22.85 | filing |
| 2 Sep 2026filed 4 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K615 at $23.74 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —8,141 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —13,313 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —13,313 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —8,141 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —472 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —398 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,433 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,433 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —398 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —398 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —472 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —398 | filing |
News
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDNLI · themarketsdaily.com · 19 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonDNLI · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Nancy Thornberry; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.